Dexcom announces availability of G7 CGM device

DexCom, a continuous glucose monitoring specialist, has announced that the Dexcom G7 Continuous Glucose Monitoring (CGM) System is now available for people with diabetes age two years and older in the UK, Ireland, Germany, Austria and Hong Kong – marking the first major milestone in the availability of the technology.

The company is also working to introduce G7 in New Zealand and South Africa in the weeks ahead, with additional markets planned soon after.

Kevin Sayer, chairman, president and CEO of Dexcom, said: “Since Dexcom G6 came to market, we’ve eliminated over 15 billion fingerpricks^‡ and helped improve the lives of more than 1.25 million people with diabetes around the world. We’re thrilled to begin the global rollout of Dexcom G7, our next-generation CGM technology, that vastly improves upon what everyone loves about G6. Dexcom CGM has become the gold standard of care for diabetes, and bringing our technology to more and more people around the world continues to be a top priority. With this initial launch behind us, we look forward to introducing G7 in additional markets and bringing this life-changing technology to as many people as we can.” 

To introduce the new device, Dexcom hosted a global streaming launch event that delivered a behind-the-scenes look at the making of G7 and featured first-hand accounts from Dexcom Warriors from around the world discussing how Dexcom CGM has changed their lives.  

The event also included comments from Dexcom leadership and key members of the G7 project team – Kevin Sayer, CEO; Jake Leach, COO; Anne Santoro, VP, global customer experience; Apurv Kamath, senior VP, product, global marketing; and Alex Diener, senior director, global product design.

The company says Dexcom G7’s low-profile, all-in-one wearable warms up faster than any other CGM on the market, sending real-time glucose readings automatically to a compatible smart device or receiver, with no finger sticks or scanning required.